News
ACAD
21.84
+0.65%
0.14
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Show Mixed Recent Momentum
Simply Wall St · 14h ago
Weekly Report: what happened at ACAD last week (0601-0605)?
Weekly Report · 2d ago
Weekly Report: what happened at ACAD last week (0525-0529)?
Weekly Report · 06/01 09:32
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan
TipRanks · 05/29 21:04
ACADIA Pharmaceuticals shareholders approved 5.21 million-share increase to 2024 equity plan
PUBT · 05/29 20:07
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
NASDAQ · 05/27 12:48
Weekly Report: what happened at ACAD last week (0518-0522)?
Weekly Report · 05/25 09:33
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)
TipRanks · 05/22 13:30
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts
Simply Wall St · 05/21 07:27
Weekly Report: what happened at ACAD last week (0511-0515)?
Weekly Report · 05/18 09:33
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story
Simply Wall St · 05/17 04:37
Biopharmas look to China, elsewhere for partnerships, R&D
Seeking Alpha · 05/14 18:40
BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks · 05/11 12:05
Weekly Report: what happened at ACAD last week (0504-0508)?
Weekly Report · 05/11 09:32
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
Simply Wall St · 05/10 22:21
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns
Simply Wall St · 05/08 22:00
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 05/08 20:52
ACADIA Pharmaceuticals Price Target Cut to $32.00/Share From $33.00 by Citigroup
Dow Jones · 05/08 20:52
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32
Benzinga · 05/08 20:43
Guggenheim Keeps Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks · 05/08 11:44
More
Webull provides a variety of real-time ACAD stock news. You can receive the latest news about Acadia Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.